Natera on Thursday announced a new study within the Phase II I-SPY 2 trial that will evaluate the ability of its Signatera minimal residual disease test to monitor breast cancer patients' response to neoadjuvant therapy.

Ibex Medical Analytics (Ibex) has launched a breast cancer biomarker scoring tool powered by artificial intelligence (AI) to help clinicians with treatment decisions.

Paige is enhancing its suite of AI-enabled solutions designed to support pathologists in the diagnosis of breast cancer while decreasing subjectivity and the tedium of manual analysis.

Breast Cancer Canada said on Thursday that it has launched a new grant program in collaboration with AstraZeneca Canada and Illumina.

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment.

Pfizer and Thermo Fisher Scientific Inc. announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia.

Sysmex Europe and Cerca Biotech said Monday that they have inked a deal for Sysmex to distribute Cerca's molecular breast cancer assay in 13 European markets.

Precision oncology company Guardant Health announced on Monday that FDA has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic.

Aiforia Technologies said Wednesday that it has received CE-IVD marking for an artificial intelligence model that helps detect progesterone-positive tumor cells.

Liquid biopsy performed on serum samples taken from breast cancer patients can provide increasingly accurate information on cancer progression and enable earlier detection of cancer recurrence, a new study from the University of Eastern Finland and Kuopio University Hospital shows.